STERIS plc (STE) financials: revenue, earnings and cash flow
Fiscal 2017–2026 + TTM · from SEC filings · data as of November 13, 2026
Summary
STERIS’s revenue went from $2.6B in fiscal 2017 to $5.9B in fiscal 2026, growth of about 9.5% a year.
Net income in fiscal 2026 was $782M, a net margin of 13.2%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $6.2B and net income $827M.
Free cash flow was $972M in fiscal 2026 and positive in 10 of the 10 years shown.
The diluted share count rose 15% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.2B | $5.9B | $5.5B | $5.1B | $4.5B | $4.2B | $3.1B | $3.0B | $2.8B | $2.6B | $2.6B |
| Gross profit | $2.7B | $2.6B | $2.4B | $2.2B | $2.0B | $1.9B | $1.3B | $1.3B | $1.2B | $1.1B | $1.0B |
| Operating income | $1.2B | $1.1B | $867M | $836M | $791M | $478M | $548M | $537M | $411M | $400M | $226M |
| Net income | $827M | $782M | $615M | $378M | $107M | $244M | $397M | $408M | $304M | $291M | $110M |
| EPS (diluted) | $8.42 | $7.93 | $6.20 | $3.81 | $1.07 | $2.48 | $4.63 | $4.76 | $3.55 | $3.39 | $1.28 |
| R&D | $118M | $113M | $108M | $104M | $98M | $87M | $66M | $66M | $63M | $61M | $59M |
| Revenue growth | — | +8.7% | +6.2% | +13.3% | +7.4% | +35.9% | +2.5% | +8.9% | +6.2% | +0.3% | — |
Cash flow
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.3B | $1.3B | $1.1B | $973M | $757M | $685M | $690M | $591M | $540M | $458M | $424M |
| Capital spending | -$352M | -$369M | -$370M | -$360M | -$362M | -$288M | -$239M | -$215M | -$190M | -$165M | -$173M |
| Free cash flow | $937M | $972M | $778M | $613M | $395M | $397M | $450M | $376M | $350M | $292M | $251M |
| Dividends paid | $252M | $242M | $220M | $201M | $183M | $163M | $134M | $123M | $113M | $103M | $93M |
| Buybacks | $340M | $236M | $211M | $12M | $309M | $56M | $15M | $51M | $81M | $65M | $98M |
| Stock-based pay | $63M | $62M | $57M | $56M | $39M | $58M | $26M | $24M | $24M | $22M | $19M |
Balance sheet
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $440M | $172M | $207M | $208M | $348M | $221M | $320M | $221M | $202M | $283M |
| Debt | — | $2.1B | $2.2B | $3.4B | $3.2B | $3.3B | $1.8B | $1.2B | $1.2B | $1.3B | — |
| Equity | — | $7.2B | $6.6B | $6.3B | $6.1B | $6.5B | $3.9B | $3.4B | $3.2B | $3.2B | $2.8B |
| Total assets | — | $10.7B | $10.1B | $11.1B | $10.8B | $11.4B | $6.6B | $5.4B | $5.1B | $5.2B | — |
| Shares (diluted) | 98M | 99M | 99M | 99M | 100M | 98M | 86M | 86M | 85M | 86M | 86M |
Margins and returns
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 44.6% | 44.2% | 44.0% | 43.2% | 43.7% | 44.6% | 43.2% | 43.5% | 42.2% | 41.7% | 39.3% |
| Operating margin | 19.0% | 18.6% | 15.9% | 16.3% | 17.4% | 11.3% | 17.6% | 17.7% | 14.8% | 15.3% | 8.7% |
| Net margin | 13.4% | 13.2% | 11.3% | 7.4% | 2.4% | 5.8% | 12.8% | 13.5% | 10.9% | 11.1% | 4.2% |
| FCF margin | 15.2% | 16.4% | 14.2% | 11.9% | 8.7% | 9.4% | 14.5% | 12.4% | 12.6% | 11.2% | 9.6% |
| ROIC | — | 8.9% | 7.6% | 6.8% | 6.9% | 3.8% | 7.4% | 9.6% | 7.8% | 7.3% | 4.8% |
| ROE | — | 10.9% | 9.3% | 6.0% | 1.8% | 3.7% | 10.2% | 12.0% | 9.6% | 9.1% | 3.9% |
Frequently asked questions
What is STERIS’s annual revenue?
$5.9B in fiscal 2026 and $6.2B over the twelve months to September 30, 2026.
How much profit does STERIS make?
Net income was $782M in fiscal 2026 (net margin 13.2%).
Is STERIS’s revenue growing?
Yes: revenue rose 8.7% in fiscal 2026 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.